Download a PDF version of the programme HERE (may be subject to change)

We are excited to announce the following keynote speakers:

Dr. Nicholas NavinGenetics & Bioinformatics, MD Anderson

Dr. Navin is an associate professor at MD Anderson Cancer Center, with a joint appointment in the Department of Genetics and the Department of Bioinformatics. He is also the co-director of the Sequencing and Microarray Core Facility at MD Anderson. He conducted his graduate training and postdoctoral training at the Cold Spring Harbor laboratory under the mentorship of Dr. Michael Wigler. During this time, he invented the first single cell DNA sequencing method (Single-Nucleus-Sequencing) for sequencing the genome of a mammalian cell (Navin et al. 2011, Nature.).This work played a pivotal role in establishing the field of single cell genomics. The Navin laboratory continues to be at the forefront of the single cell cancer genomics field, where they have discovered a punctuated model of copy number evolution in triple-negative breast cancer (Gao et al. 2016, Nature Genetics) and elucidated the role mutator phentoypes and subclonal mutations in breast cancer evolution (Wang et al. 2014, Nature). Dr. Navin’s group continues to pioneer the developing novel technologies for performing single cell DNA and RNA sequencing, in addition to innovative computational and statistical methods for analyzing the resulting large-scale datasets. These methods are being applied to study cancer evolution in the context of invasion, metastasis and therapy resistance. His laboratory works closely with leading oncologists and pathologist at MD Anderson to translate these technologies into the clinic, where they are poised to make a major impact on reducing the morbidity in human patients. Dr. Navin has been the recipient of many prestigious awards in recognition of his work, including the Damon-Runyon Innovator Award, AAAS Wachtel Award, ACS Research Scholar Award, Wilson Stone Award and the Randall Innovator Award..

Prof. Dr. Karin de VisserTumor Biology & Immunology, NKI

Prof. dr. Karin E. de Visser obtained her PhD at the Division of Immunology at the Netherlands Cancer Institute in Amsterdam in the field of tumor immunotherapy. From 2003-2005 she worked as a postdoctoral fellow in the lab of Prof. dr. Lisa Coussens at the University of California, San Francisco, where she developed an active interest in the interplay between the adaptive and innate immune system during cancer development.In 2005 she joined the laboratory of Prof. dr. Jos Jonkers at the Division of Molecular Biology at the Netherlands Cancer Institute, where she expanded her research direction into the field of inflammation and mammary carcinogenesis, using conditional mouse models. Currently she is group leader at the Division of Tumor Biology & Immunology at the Netherlands Cancer Institute, alongside her appointment as group leader at Oncode Institute and as professor of Experimental Immunobiology of Cancer at Leiden University Medical Center. The overall goal of her research is to understand by which mechanisms the immune system influences metastatic breast cancer and response to conventional anti-cancer therapies. Through mechanistic understanding of the crosstalk between the immune system and cancer cells she aims to contribute to the design of novel immunomodulatory strategies to fight metastatic breast cancer. Karin de Visser received an ERC consolidator grant in 2014 and a prestigious NWO-VICI grant in 2019, she is recipient of the 2015 Metastasis Research Prize of the Beug Foundation and in 2016 she was selected as a member of the EMBO young investigator program.

Prof. Dr. Ben FeringaOrganic Chemistry and Nanobiology, RUG

Bernard Lucas “Ben” Feringa is a Dutch synthetic organic chemist, specializing in molecular nanotechnology and homogenous catalysis. He is the Jacobus van ‘t Hoff Distinguished Professor of Molecular Sciences  at the Stratingh Institute for Chemistry, University of Groningen, Netherlands, and an Academy Professor and Chair of Board of the Science Division of the Royal Netherlands Academy of Sciences. He was awarded the 2016 Nobel Prize in Chemistry, together with Sir J. Fraser Stoddart and Jean-Pierre Sauvage, “for the design and synthesis of molecular machines”.

Feringa received his MSc degree with distinction from the University of Groningen in 1974. He subsequently obtained a PhD degree at the same university in 1978, with the thesis titled “Asymmetric oxidation of phenols. Atropisomerism and optical activity”. Following a short period at Shell in the Netherlands and the United Kingdom, he was appointed as lecturer at the University of Groningen in 1984 and Full Professor, succeeding Prof Wijnberg, in 1988. In the 1990s, Feringa’s work in stereochemistry led to major contributions in photochemistry, resulting in the first monodirectional light driven molecular rotary motor and later a molecular car (a so-called nanocar) driven by electrical impulses. Ben Feringa holds over 30 patents and has published over 650 peer reviewed research papers to date, cited more than 30,000 times and has an h-index in excess of 90. He has guided over 100 PhD students over his career.

Dr. Andrea van Elsas – Aduro  Biotech

Andrea van Elsas became Chief Scientific Officer (CSO) in September 2017, following his tenure as Chief Scientific Officer of Aduro Biotech Europe since November 2015. Prior to its acquisition by Aduro in 2015, Dr. Andrea van Elsas co-founded BioNovion and served as Chief Scientific Officer focusing on the development of innovative therapeutic antibodies in the field of immune oncology. From 1999 to 2011, he held numerous positions at Organon in Oss, The Netherlands, and Cambridge, Massachusetts (acquired by Schering-Plough Corporation in 2007 and later by Merck & Co.), and as the Director of Tumor Immunology he ran the immune oncology portfolio including the program that later became known as pembrolizumab. As a postdoctoral researcher from 1997-1999, Andrea worked at the University of California, Berkeley, studying antibodies blocking CTLA-4 for the treatment of cancer and is a co-inventor on the original patents that formed the basis for the development of Yervoy® (ipilimumab), the first checkpoint inhibitor approved in 2011 by the U.S. Food and Drug Administration for the treatment of melanoma.